CA2559062A1 - Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor - Google Patents

Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor Download PDF

Info

Publication number
CA2559062A1
CA2559062A1 CA002559062A CA2559062A CA2559062A1 CA 2559062 A1 CA2559062 A1 CA 2559062A1 CA 002559062 A CA002559062 A CA 002559062A CA 2559062 A CA2559062 A CA 2559062A CA 2559062 A1 CA2559062 A1 CA 2559062A1
Authority
CA
Canada
Prior art keywords
aat
leu
lys
thr
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002559062A
Other languages
English (en)
French (fr)
Inventor
Philip A. Pemberton
Philip J. Barr
Helen L. Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arriva Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2559062A1 publication Critical patent/CA2559062A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D1/00—Cigars; Cigarettes
    • A24D1/002—Cigars; Cigarettes with additives, e.g. for flavouring
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter tips or filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces of cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA002559062A 2004-03-09 2005-03-09 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor Abandoned CA2559062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55185604P 2004-03-09 2004-03-09
US60/551,856 2004-03-09
PCT/US2005/007959 WO2005086915A2 (en) 2004-03-09 2005-03-09 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor

Publications (1)

Publication Number Publication Date
CA2559062A1 true CA2559062A1 (en) 2005-09-22

Family

ID=34976236

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002559062A Abandoned CA2559062A1 (en) 2004-03-09 2005-03-09 Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor

Country Status (6)

Country Link
US (1) US7914771B2 (enExample)
EP (1) EP1737499A4 (enExample)
JP (1) JP2007528409A (enExample)
AU (1) AU2005221151A1 (enExample)
CA (1) CA2559062A1 (enExample)
WO (1) WO2005086915A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
RU2433841C2 (ru) * 2006-02-09 2011-11-20 Пари Фарма Гмбх Доставка в легкие альфа-1-ингибитора протеиназ
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
GB0716026D0 (en) * 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
SMT201900520T1 (it) * 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
RU2639526C2 (ru) * 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
BR112014007127A2 (pt) * 2011-12-30 2017-04-04 Grifols Sa métodos para retardar o início ou diminuir a progressão de um ou mais sintomas, para retardar o início ou a progressão de um ou mais sintomas, para identificar um indivíduo em necessidade de terapia de manutenção de a1pi, e para identificar indivíduos com risco elevado para exacerbações pulmonares, uso de a1pi, aparelho e meio para a administração aerossolizada de a1pi para a inalação, e, kit
US20160011207A1 (en) * 2012-12-07 2016-01-14 Virginia Commonwealth University Diagnosis and therapy of chronic inflammation-induced disorders
CN105592854A (zh) * 2013-08-05 2016-05-18 杰拉德·沃尔曼 使吸烟的不利作用减少的新方法
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
WO2018116300A1 (en) * 2016-12-22 2018-06-28 Kamada Ltd. Dry powder formulations of alpha-1 antitrypsin
EP3915574A1 (en) * 2020-05-27 2021-12-01 Grifols Worldwide Operations Limited Method for the treatment of cytokine release syndrome
KR20230116786A (ko) 2020-12-01 2023-08-04 리버스피에이에이치 엘엘씨 만성 폐쇄성 폐질환, 천식, 폐렴, 기관지염, 낭포성 섬유증, 폐부종, 간질성 폐 질환, 사르코이드증, 특발성 폐섬유증, 급성 호흡곤란 증후군 및 폐동맥 고혈압을 치료하기 위한 방법 및 조성물
US11324694B1 (en) * 2021-10-28 2022-05-10 Cmpd Licensing, Llc Nebulization formulations for delivery to lower respiratory tract
WO2023091081A2 (en) * 2021-11-16 2023-05-25 Agency For Science, Technology And Research Inhalable recombinant protein powder formulation for treating genetic and autoimmune disorders
EP4480493A1 (en) * 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4083372A (en) 1976-05-24 1978-04-11 Robert Boden Cigarette-simulating inhaler
US4393884A (en) 1981-09-25 1983-07-19 Jacobs Allen W Demand inhaler for oral administration of tobacco, tobacco-like, or other substances
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4870008A (en) * 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4732973A (en) * 1984-06-14 1988-03-22 Chiron Corporation Active site modified protease α-1-antitrypsin inhibitors
US4752576A (en) * 1984-06-14 1988-06-21 Chiron Corporation Expression of α-1 antitrypsin in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4735217A (en) 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4765348A (en) 1986-12-12 1988-08-23 Brown & Williamson Tobacco Corporation Non-combustible simulated cigarette device
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US5093316A (en) * 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US5290762A (en) * 1986-12-24 1994-03-01 John Lezdey Treatment of inflammation
US5166134A (en) * 1986-12-24 1992-11-24 John Lezdey Treatment of allergic rhinitis
JP2656944B2 (ja) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5159940A (en) 1988-07-22 1992-11-03 Philip Morris Incorporated Smoking article
US4892109A (en) 1989-03-08 1990-01-09 Brown & Williamson Tobacco Corporation Simulated smoking article
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5114953A (en) 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
US5287850A (en) 1991-08-20 1994-02-22 Habley Medical Technology Corporation Timing and velocity controlled powered pharmaceutical inhaler
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
FR2696080B1 (fr) 1992-09-30 1994-12-23 Jesus Covarrubias Filtre à cigarette pour l'administration de taurine par inhalation.
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
AU671724B2 (en) 1993-03-16 1996-09-05 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as metalloproteinase inhibitors
CA2160139A1 (en) 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US6037472A (en) 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
DE19541873A1 (de) 1995-11-09 1997-05-15 Rhodia Ag Rhone Poulenc Filterzigarette
WO1997042168A1 (en) 1996-05-06 1997-11-13 Zeneca Limited Thio derivatives of hydroxamic acids
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
US6610683B2 (en) * 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
ES2178759T3 (es) 1996-10-02 2003-01-01 Novartis Ag Derivados de acido hidroxamico.
EP0971881A1 (en) 1997-03-28 2000-01-19 AstraZeneca AB Process for the preparation of n-(3-hydroxy-succinyl)-amino acid derivatives
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
US20010006939A1 (en) 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
BR9814422A (pt) * 1997-12-23 2000-10-10 Warner Lambert Co Combinações de inibidor de ace - inibidor de mmp
GB9804504D0 (en) 1998-03-03 1998-04-29 Leo Pharm Prod Ltd Matrix metalloproteinase inhibitors
US5996589A (en) 1998-03-03 1999-12-07 Brown & Williamson Tobacco Corporation Aerosol-delivery smoking article
CN1333750A (zh) 1998-12-09 2002-01-30 美国家庭用品有限公司 含乙酰胺和取代的乙酰胺的疱疹病毒硫脲抑制剂
WO2000051623A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001029025A2 (en) 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
GB0004531D0 (en) * 2000-02-25 2000-04-19 Richards Andrew J M The treatment of respiratory diseases
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6637430B1 (en) 2000-06-16 2003-10-28 Ponwell Enterprises Limited Respiratory delivery system with power/medicament recharge assembly
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
JP4426179B2 (ja) 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ，インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
EP1351678A2 (en) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6789546B2 (en) 2001-06-26 2004-09-14 Technion Research & Development Foundation Ltd. Filters for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject
WO2003035610A1 (en) * 2001-10-26 2003-05-01 Shionogi & Co., Ltd. Sulfonamide derivative having mmp inhibitory activity
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
ES2565028T3 (es) 2002-02-18 2016-03-30 Ockham Biotech Limited Terapia de combinación para trastornos respiratorios
AU2003214108A1 (en) 2002-03-08 2003-09-22 Novartis Ag Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
CA2483515A1 (en) * 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, method for producing the same and use thereof
US7165362B2 (en) * 2002-07-15 2007-01-23 Apple Computer, Inc. Glass support member
US6810883B2 (en) 2002-11-08 2004-11-02 Philip Morris Usa Inc. Electrically heated cigarette smoking system with internal manifolding for puff detection
EP1624866A2 (en) 2003-05-16 2006-02-15 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
US20060205671A1 (en) 2003-07-02 2006-09-14 Jakob Vinten-Johansen Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
PT1684719E (pt) * 2003-11-14 2012-02-03 Baxter Int Composições de alfa-1-antitripsina e métodos de tratamento utilizando estas composições
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor

Also Published As

Publication number Publication date
JP2007528409A (ja) 2007-10-11
WO2005086915A2 (en) 2005-09-22
EP1737499A4 (en) 2009-07-22
US20050201951A1 (en) 2005-09-15
US7914771B2 (en) 2011-03-29
EP1737499A2 (en) 2007-01-03
AU2005221151A1 (en) 2005-09-22
WO2005086915A3 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
US7914771B2 (en) Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US10927166B2 (en) Compositions comprising an anti-C5 antibody
JP2656944B2 (ja) タンパク質性治療剤のエアロゾール化
ES2664624T3 (es) Alfa-I antitripsina para tratar episodios de exacerbación de enfermedades pulmonares
AU738298B2 (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US20100124536A1 (en) Hemophilia Treatment by Inhalation of Coagulation Factors
AU691514B2 (en) Stabilization of aerosolized proteins
JP2011001383A (ja) 肺病態の治療および予防
ES2887358T3 (es) Inhibidor de Alfa1-Proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares
KR20160054475A (ko) 흡연의 해로운 영향을 감소시키는 신규의 수단
Vogelmeier et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers.
WO2005049801A2 (en) Dry protein formulation
Stockleyb et al. Neutrophil elastase inhibitors
MXPA00003231A (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued